Teladoc Health (NYSE:TDOC) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $-1.66–1.52 for the period, compared to the Thomson Reuters consensus estimate of $-1.55. The company issued revenue guidance of $535-545 million, compared to the consensus revenue estimate of $541.73 million.Teladoc Health also updated its FY19 guidance to ($1.66)-($1.52) EPS.
Shares of TDOC stock traded down $0.05 during trading hours on Thursday, hitting $57.95. 1,265,805 shares of the company’s stock were exchanged, compared to its average volume of 1,654,444. The company has a market capitalization of $4.16 billion, a PE ratio of -40.24 and a beta of 1.38. Teladoc Health has a 12-month low of $40.00 and a 12-month high of $89.05. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.53 and a current ratio of 8.53.
Teladoc Health (NYSE:TDOC) last issued its earnings results on Tuesday, April 30th. The health services provider reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Teladoc Health had a negative net margin of 22.63% and a negative return on equity of 11.13%. The company had revenue of $128.57 million for the quarter, compared to the consensus estimate of $127.99 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The firm’s revenue for the quarter was up 43.4% on a year-over-year basis. On average, research analysts predict that Teladoc Health will post -1.53 EPS for the current year.
Several brokerages recently commented on TDOC. Craig Hallum reaffirmed a buy rating and issued a $70.00 target price (down from $80.00) on shares of Teladoc Health in a research note on Wednesday. Cantor Fitzgerald reaffirmed a hold rating and issued a $70.00 target price on shares of Teladoc Health in a research note on Tuesday. Guggenheim began coverage on shares of Teladoc Health in a research note on Wednesday, April 17th. They issued a buy rating on the stock. Stephens began coverage on shares of Teladoc Health in a research note on Tuesday, April 16th. They issued an overweight rating and a $75.00 target price on the stock. Finally, Zacks Investment Research raised shares of Teladoc Health from a sell rating to a hold rating in a research note on Monday, April 8th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Teladoc Health presently has an average rating of Buy and an average target price of $81.00.
In other Teladoc Health news, insider Lewis Levy sold 675 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $56.80, for a total transaction of $38,340.00. Following the transaction, the insider now directly owns 4,805 shares of the company’s stock, valued at approximately $272,924. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 30,000 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $69.68, for a total transaction of $2,090,400.00. Following the transaction, the chief executive officer now directly owns 631,875 shares in the company, valued at $44,029,050. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,221 shares of company stock worth $9,944,891. Insiders own 3.95% of the company’s stock.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.